Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications CTL Cells, VST Cells G-Rex®10

Publication Date: July 17, 2012

Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections

A single stimulation of donor blood cells with peptide libraries can generate polyclonal CD4+ and CD8+ cytotoxic T lymphocytes specific for 15 antigens from seven viruses within 10 days. Pulsing PBMCs with 15mer pepmixes and culturing them in IL4 plus IL7 produced Th1-polarized lines that were 92.6% CD3+, with no regulatory T cell outgrowth. Pooling all pepmixes into one mastermix gave the same specificity as stimulating with separate virus pools. Seeding 1.5 × 10^7 PBMCs in a G-Rex® regularly yielded 1 × 10^8 CTLs in 10 days, and restimulation with pepmix-pulsed PHA blasts gave a further 8.4-fold expansion over 7 days. Antigen-specific cells made up 67.7 ± 13.3% of T cells in six multivi…

Download Now →

Author: Ulrike Gerdemann, Jacqueline M Keirnan +11 more

Publications TCR T Cells, TIL Cells

Publication Date: April 4, 2012

Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE®

A WAVE bioreactor with perfusion expanded tumor-infiltrating lymphocytes and TCR-transduced peripheral blood lymphocytes to clinical numbers, matching gas-permeable static bags in cell yield. TIL were expanded from day 7 of a rapid expansion protocol after a first week in T175 flasks. Mean harvests were 4.5 × 10^10 cells from static bags (n = 25) and 4.4 × 10^10 from the WAVE (n = 27), with mean fold expansions of 1259 and 1130. WAVE cultures held glucose and lactate more steadily, contained more CD4+ and fewer CD8+ cells, and had fewer tetramer-positive transduced cells. TCR-transduced cells released more IFN-γ against peptide-pulsed T2 cells. TIL expanded in the WAVE were given to 25 pa…

Download Now →

Author: Robert PT Somerville, Laura Devillier +3 more

Publications TIL Cells G-Rex®10, G-Rex®100

Publication Date: April 1, 2012

Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable to Numbers Needed for Patient Treatment

Melanoma tumor infiltrating lymphocytes (TIL) can be initiated and rapidly expanded to treatment-scale numbers in gas-permeable G-Rex® flasks instead of 24-well plates, T-175 flasks and bags. In initial culture, G-Rex®10 flasks yielded TIL from 13 of 14 tumor digests with viability and CD3/CD8 phenotype similar to 24-well plates, and tumor fragments gave consistently higher yields per vessel. During rapid expansion, 5 × 10^6 TIL in a G-Rex®100 flask grew 176-fold in 7 days, versus 167-fold in T-175 flasks. A two-step 14-day process using TIL from 14 patients produced 8.60 ± 0.75 × 10^9 TIL per starting flask, a full-scale nine-flask run reached 23.6 × 10^9 cells, and interferon-γ release…

Download Now →

Author: Jianjian Jin, Marianna Sabatino +5 more

Publications CTL Cells, VST Cells

Publication Date: January 1, 2012

Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein–Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant

Trivirus-specific cytotoxic T lymphocytes targeting Epstein–Barr virus, cytomegalovirus and adenovirus can be manufactured under GMP from a single 60 mL blood draw of a CMV-seropositive stem cell donor and used prophylactically after transplant. Donor monocytes transduced with an adenoviral vector expressing CMV-pp65 start the culture, and later stimulations use irradiated, vector-transduced autologous EBV-LCL, in 24-well plates or a G-Rex® gas permeable device, with IL-2 added 3–4 days after the first stimulation. Since 2004, 26 patients received these cells prophylactically in a phase I/II trial, and cryopreservation followed a median of three stimulations (range 2–6). Release criteria…

Download Now →

Author: Uluhan Sili, Ann M. Leen +6 more

Publications CTL Cells

Publication Date: September 13, 2011

Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma

Cytotoxic T lymphocytes targeting several lymphoma-associated antigens at once can be grown in a single culture, which could extend T-cell therapy to EBV-negative Hodgkin and non-Hodgkin lymphoma. Blood cells were stimulated with dendritic cells loaded with overlapping peptide libraries spanning SSX2, MAGE-A4 and Survivin, with PRAME and NY-ESO-1 added for some patients, in the presence of IL-7, IL-12 and IL-15 plus either IL-6 or IL-27. Lines specific for at least two of the three antigens were obtained from nine of nine healthy donors. Most T cells reactive to SSX2 and MAGE-A4 produced both IFN-γ and TNF-α. The lines lysed peptide-loaded targets, HLA-matched lymphoma cell lines and auto…

Download Now →

Author: Ulrike Gerdemann, Usha Katari +12 more

Publications CTL Cells G-Rex®10, G-Rex®100, G-Rex®100M, G-Rex®10M

Publication Date: September 11, 2011

Optimization Manufacture of Virus- and Tumor-Specific T Cells

Culturing virus-specific T cells in gas-permeable G-Rex® flasks simplifies manufacture compared with 24-well plates, raising cell output while reducing handling and culture time. This review compares conventional multiwell plates, bags, and bioreactors with the G-Rex® and describes the Baylor group's EBV-specific CTL process. PBMCs are cocultured with irradiated EBV-LCLs at 40:1 in a G-Rex®10 with 40 mL of medium, then, once cells have expanded, moved to a G-Rex®100 with 500 mL. Traditional 24-well cultures often run eight weeks or longer to reach clinical cell numbers. The authors report 3–20-fold greater cell output and about four-fold fewer technician interventions. The process was tra…

Download Now →

Author: Natalia Lapteva, Juan F. Vera

Publications CAR T Cells, VST Cells G-Rex®10

Publication Date: July 19, 2011

PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor

Epstein-Barr virus-specific T cells can be engineered with the nonviral piggyBac transposon to express a HER2-specific chimeric antigen receptor while keeping their virus specificity and killing HER2-positive tumor cells. Donor blood cells were nucleofected with CAR and truncated CD19 transposons, stimulated with autologous EBV-transformed B cell lines and CD19-selected, which raised CAR-positive cells to 47.9% on average. The protocol gave about 30 × 10^6 dually specific T cells from roughly 10 mL of blood in about 30 days, and CAR expression remained stable beyond 100 days of culture. In SCID mice with intracranial HER2-positive tumors, one intratumoral dose of 2 × 10^6 HER2-CTLs caused…

Download Now →

Author: Yozo Nakazawa, Leslie E Huye +8 more

Publications CTL Cells G-Rex®10

Publication Date: July 5, 2011

SOP: D03.31.22 INITIATION OF EBV- OR ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTES (CTL)

This GMP standard operating procedure describes how to start cytotoxic T cell lines specific for Epstein-Barr virus or for a chosen antigen from patient or donor blood cells. Responder PBMC are stimulated at 2 × 10^6 cells per mL with irradiated autologous lymphoblastoid cells at a 40:1 ratio, or with adenovirus-transduced dendritic cells or monocytes. Cultures grow in 24-well plates or in a GRex40 bioreactor, which holds 1 × 10^7 PBMC and is brought to 30 mL, for 7 to 9 days. A second stimulation follows on days 9 to 12, provided viability exceeds 60%, and IL-2 is then added at 50 to 100 units per mL. The SOP also gives a worked dose calculation.

Download Now →

Author: Cliona Rooney, Oumar Diouf +2 more

Publications CTL Cells

Publication Date: July 5, 2011

SOP: D03.14.23 ADENOVIRUS TRANSDUCTION OF B95-8+ LCL FOR CTL STIMULATION

This GMP standard operating procedure describes how Epstein-Barr virus-transformed B95-8+ lymphoblastoid cell lines are transduced with adenovirus vectors so they can serve as antigen-presenting stimulators for clinical-grade cytotoxic T cells. Cells are mixed with Ad-LMP1-I-LMP2 at 15,000 viral particles per cell or Ad-CMVpp65 at 100 viral particles per cell, incubated about 90 minutes, then cultured at 5 × 10^5 cells/mL in 24-well plates for 2 days. Transduced cells are irradiated at 40 Gy, washed and resuspended at 2.5 × 10^5 cells/mL in CTL medium. The expected result is greater than 70% viability of transduced cells.

Download Now →

Author: Cliona Rooney, Catherine Bollard +2 more

Publications CTL Cells, VST Cells

Publication Date: March 1, 2011

Manufacture of GMP-grade Cytotoxic T Lymphocytes specific for LMP1 and LMP2 for Patients with EBV-associated Lymphoma

Baylor College of Medicine's GMP process makes cytotoxic T lymphocytes (CTLs) specific for the EBV latent membrane proteins LMP1 and LMP2 to treat relapsed EBV-positive lymphoma with type II latency, an approach used since 2004 in over 35 patients in phase I/II trials, with objective responses in 11 of 16 patients and 8 complete remissions. CTL lines are initiated from patient or donor PBMCs with antigen-presenting cells expressing LMP1 and LMP2 from a replication-incompetent adenovirus vector in the presence of IL-15, then expanded with transduced LCLs and IL-2. Later LCL stimulations can be done in 24-well plates or in the G-Rex® gas-permeable device at responder-to-stimulator ratios of…

Download Now →

Author: Catherine M. Bollard, Stephen Gottschalk +4 more

Publications CTL Cells G-Rex®10, G-Rex®100

Publication Date: February 8, 2011

SOP: D03.32.21 EXPANSION OF EBV- OR ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTES (CTL)

This standard operating procedure from a Houston GMP facility describes how to expand EBV-specific and antigen-specific cytotoxic T lymphocytes to meet patient dose, quality-control and research needs. T cells are restimulated with irradiated autologous lymphoblastoid cell lines, in either 24-well plates or GRex flasks. In GRex flasks, responder cells are resuspended at 1 × 10^6 cells per mL and combined with LCLs at a 5:1 ratio, with IL-2 at 50 to 100 units per mL. Cells with viability above 60% proceed directly; otherwise dead cells are removed on Lymphoprep gradients. Cultures can be expanded in the bioreactor for up to 16 to 18 days. Expected results are sufficient CTL numbers for inf…

Download Now →

Author: Cliona Rooney, Oumar Diouf +2 more

Publications CTL Cells

Publication Date: June 8, 2010

SOP: D03.05.22 CHARACTERIZATION AND FREEZING OF CYTOTOXIC T-LYMPHOCYTES

This GMP standard operating procedure describes how ex vivo expanded cytotoxic T lymphocytes are harvested, characterized, sampled for safety testing and cryopreserved for patient dosing. Cells are harvested from wells or GRex flasks, counted, and aliquots are reserved for mycoplasma PCR, HLA typing, phenotyping and cytotoxicity. The remaining cells are washed four times at 400 × g in HBSS with 10% HSA, then resuspended in ice-cold freezing medium of 10% DMSO, 50% HSA and 40% HBSS at up to 10^7 cells/ml. They are frozen in a controlled-rate freezer and stored in liquid nitrogen. Release requires viability of at least 70%, negative bacterial, fungal and mycoplasma tests, endotoxin below th…

Download Now →

Author: Cliona Rooney, Catherine Bollard +2 more